Last reviewed 2026-05-23 · How we verify

Stamaril, Sanofi Pasteur

Epicentre · FDA-approved active Biologic ✓ Verified May 2026

Stamaril, Sanofi Pasteur is a Live attenuated vaccine Biologic drug developed by Epicentre. It is currently FDA-approved for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas.

Stamaril is a live attenuated yellow fever vaccine that stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus.

Stamaril is a Yellow Fever vaccine developed by Sanofi Pasteur. It is a small molecule vaccine, classified as a small molecule modality.

At a glance

Generic name	Stamaril, Sanofi Pasteur
Sponsor	Epicentre
Drug class	Live attenuated vaccine
Target	Yellow fever virus (17D strain)
Modality	Biologic
Therapeutic area	Immunology / Infectious Disease
Phase	FDA-approved

Mechanism of action

The vaccine contains a weakened strain of yellow fever virus (17D strain) that replicates in vaccinated individuals without causing disease, triggering both humoral (antibody) and cell-mediated immune responses. This provides long-term protection against infection with wild-type yellow fever virus. The vaccine is administered as a single dose and confers immunity in approximately 95% of vaccinees within 30 days.

Approved indications

Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas

Common side effects

Headache
Myalgia
Fever
Injection site reaction
Fatigue

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Stamaril, Sanofi Pasteur CI brief — competitive landscape report
Stamaril, Sanofi Pasteur updates RSS · CI watch RSS
Epicentre portfolio CI

Frequently asked questions about Stamaril, Sanofi Pasteur

What is Stamaril, Sanofi Pasteur?

Stamaril, Sanofi Pasteur is a Live attenuated vaccine drug developed by Epicentre, indicated for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas.

How does Stamaril, Sanofi Pasteur work?

Stamaril is a live attenuated yellow fever vaccine that stimulates the immune system to produce antibodies and cellular immunity against yellow fever virus.

What is Stamaril, Sanofi Pasteur used for?

Stamaril, Sanofi Pasteur is indicated for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas.

Who makes Stamaril, Sanofi Pasteur?

Stamaril, Sanofi Pasteur is developed and marketed by Epicentre (see full Epicentre pipeline at /company/epicentre).

What drug class is Stamaril, Sanofi Pasteur in?

Stamaril, Sanofi Pasteur belongs to the Live attenuated vaccine class. See all Live attenuated vaccine drugs at /class/live-attenuated-vaccine.

What development phase is Stamaril, Sanofi Pasteur in?

Stamaril, Sanofi Pasteur is FDA-approved (marketed).

What are the side effects of Stamaril, Sanofi Pasteur?

Common side effects of Stamaril, Sanofi Pasteur include Headache, Myalgia, Fever, Injection site reaction, Fatigue.

What does Stamaril, Sanofi Pasteur target?

Stamaril, Sanofi Pasteur targets Yellow fever virus (17D strain) and is a Live attenuated vaccine.

Drug class: All Live attenuated vaccine drugs
Target: All drugs targeting Yellow fever virus (17D strain)
Manufacturer: Epicentre — full pipeline
Therapeutic area: All drugs in Immunology / Infectious Disease
Indication: Drugs for Prevention of yellow fever in endemic regions and travelers to yellow fever-endemic areas

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing